Lexaria receives $2.6M tax rebate from Australian R&D program

Go back to Lexaria receives $2.6M tax rebate from Australian R&D program

Lexaria Receives USD$2.6 Million Tax Rebate Payment

September 1, 2026 9:15 AM EDT

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate

KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Lexaria strategically performed its previous 12-week... More